Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.1, 2011-01, pp. : 111-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

By Gasperini Claudio Haggiag Shalom Ruggieri Serena

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1243-1253

Informa Healthcare

Access to resources Recommend Favorite

Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis: A Retrospective Analysis of Patients Treated at a US Centre

By Brown Brandon A. Torabi Mina

Drug Safety, Vol. 34, Iss. 2, 2011-02 ,pp. : 117-123

Adis International

Access to resources Recommend Favorite

Treating multiple sclerosis with monoclonal antibodies: a 2013 update

By Deiß Annika Brecht Isabel Haarmann Axel Buttmann Mathias

Expert Review of Neurotherapeutics, Vol. 13, Iss. 3, 2013-03 ,pp. : 313-335

Informa Healthcare

Access to resources Recommend Favorite

Treating pain in multiple sclerosis

By Truini Andrea Galeotti Francesca Cruccu Giorgio

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2355-2368

Informa Healthcare

Access to resources Recommend Favorite

Antibodies as therapeutics for multiple sclerosis

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 403-413

Govi-Verlag

Access to resources Recommend Favorite